Review: Long-term anticoagulation reduces recurrent venous thromboembolism

March 2006
ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p33
Academic Journal
The article focuses on a study which revealed that long-term anticoagulation reduces recurrent venous thromboembolism (VTE). Randomized controlled trials were conducted that compared different durations of anticoagulation in patients with VTE, in which initial therapy was similar in both study groups after diagnosis and recurrent VTE was assessed. Using a random-effects model, meta-analysis showed that patients who received long-term anticoagulation had fewer recurrent VTE events than did patients who received short-term anticoagulation.


Related Articles

  • The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism. Douketis, James D.; Chu Shu Gu; Schulman, Sam; Ghirarduzzi, Angelo; Pengo, Vittorio; Prandoni, Paolo // Annals of Internal Medicine;12/4/2007, Vol. 147 Issue 11, p766 

    Background: The long-term risk for fatal pulmonary embolism (PE) after treatment of venous thromboembolism (VTE) may be an important factor in the decision to discontinue this treatment. Objective: To provide reliable and precise estimates of the annual risk for fatal PE and the case-fatality...

  • SPEED OF ANTICOAGULATION IN DVT. Douglas, Montgomery; Strelnick, Alvin // Journal of Family Practice;Mar1998, Vol. 46 Issue 3, p202 

    This article focuses on a study related to the speed of anticoagulation in deep vein thrombosis (DVT). In 1986, the researchers of the current study reported that DVT patients who failed to achieve the lower limit of activated partial thromboplastin time within the first 24 hours after receiving...

  • 6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both.  // Evidence Based Medicine;Oct2007, Vol. 12 Issue 5, p143 

    The article presents the author's view on the study "Anticoagulation for three versus six months in patients with deep thrombosis or pulmonary embolism, or both: randomized trial." He remarks that the study suggests a comparable efficacy with 3- and 6-moths of anticoagulant therapy, as both...

  • Ximelagatran—Promises and Concerns. Gurewich, Victor // JAMA: Journal of the American Medical Association;2/9/2005, Vol. 293 Issue 6, p736 

    Presents an editorial on the several studies in this issue looking at the use of ximelagatran in the treatment of thrombosis. Background on anticoagulant use; Inherent problems with warfarin treatment; Hospitalization rate of patients on vitamin K antagonists; How ximelagatran works within the...

  • New oral anticoagulants for acute venous thromboembolism.  // JAMA: Journal of the American Medical Association;2/19/2014, Vol. 311 Issue 7, p731 

    The article offers information on the latest anticoagulants for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) collectively referred to as venous thromboembolism (VTE). It highlights the findings of clinical trials on these new oral anticoagulants, such as Rivaroxaban...

  • Rapid reversal of anticoagulant bleeding- rFVIIa an option? Zupancic-Šalek, Silva // Journal of Postgraduate Medicine;Jan-Mar2007, Vol. 53 Issue 1, p3 

    The article reflects on the use of recombinant factor VIIa (rFVIIa) as a potential agent to reverse anticoagulant effects. The author offers cases wherein the rFVIIa maybe useful to reverse the effect of vitamin K antagonists in cases where standard therapy is insufficient. He stresses that the...

  • Acute Budd-Chiari Syndrome Associated with Activated Protein C Resistance During Intravenous Anticoagulant Treatment. Yildiz, B�lent O.; Oran, Bet�l; B�y�kasik, Yahya; Haznedaroglu, Ibrahim C.; �ekirge, Saruhan; Kirazli, Serafettin // Clinical & Applied Thrombosis/Hemostasis;Jul1998, Vol. 4 Issue 3, p220 

    The Budd-Chiari syndrome is a rare but serious condition defined as hepatic venous outflow obstruction. This article presents a case of acute Budd-Chiari syndrome in a 43-year-old woman with activated protein C resistance while she was being treated with intravenous heparin infusion for...

  • The influence of low molecular weight heparin on the expression of osteogenic growth factors in human fracture healing. Sarahrudi, Kambiz; Kaiser, Georg; Thomas, Anita; Michel, Mark; Wolf, Harald; Mousavi, Mehdi; Aharinejad, Seyedhossein // International Orthopaedics;May2012, Vol. 36 Issue 5, p1095 

    Purpose: Anticoagulant therapy with low molecular weight heparins (LMWH) and mechanical compression is considered the gold standard for the prevention of thrombosis. However, evidence exists that LMWHs impair bone metabolism. The aim of this study was therefore to analyse alterations in the...

  • Multiparin.  // Royal Society of Medicine: Medicines;2002, p378 

    The article presents information on the anticoagulant multiparin. It is a proprietary, prescription-only preparation of heparin. The drug can be used to treat various forms of thrombosis. It is available in a form for injection.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics